ABBV, BIIB And CELG, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 122 points (0.7%) at 17,066 as of Monday, July 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,069 issues advancing vs. 930 declining with 155 unchanged.

The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.5%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 0.8%. Top gainers within the industry include Perrigo ( PRGO), up 5.8%, Mylan ( MYL), up 2.6%, Grifols ( GRFS), up 2.5%, Shire ( SHPG), up 1.9% and Novartis ( NVS), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry lower today. As of noon trading, AbbVie is down $0.25 (-0.5%) to $54.71 on heavy volume. Thus far, 18.4 million shares of AbbVie exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $53.72-$54.85 after having opened the day at $53.89 as compared to the previous trading day's close of $54.96.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $88.7 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Friday. Currently there are 4 analysts that rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst